Page 170 - Biomarkers for risk stratification and guidance in heart failure

83. Metra M, Davison B, Bettari L, et al. Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function. Circulation Heart failure 2012;5:54-62.
84. Nohria A, Hasselblad V, Stebbins A, et al. Cardiorenal interactions: insights from the ESCAPE trial. Journal of the American College of Cardiology 2008;51:1268-74.
85. Damman K, Valente MA, Voors AA, O’Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. European heart journal 2014;35:455-69.
86. Testani JM, McCauley BD, Chen J, Coca SG, Cappola TP, Kimmel SE. Clinical characteristics and outcomes of patients with improvement in renal function during the treatment of decompensated heart failure. Journal of cardiac failure 2011;17:993-1000.
87. Testani JM, McCauley BD, Kimmel SE, Shannon RP. Characteristics of patients with improvement or worsening in renal function during treatment of acute decompensated heart failure. The American journal of cardiology 2010;106:1763-9.
88. de Silva R, Nikitin NP, Witte KK, et al. Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. European heart journal 2006;27:569-81.
89. Haase M, Muller C, Damman K, et al. Pathogenesis of cardiorenal syndrome type 1 in acute decompensated heart failure: workgroup statements from the eleventh consensus conference of the Acute Dialysis Quality Initiative (ADQI). Contributions to nephrology 2013;182:99-116.
90. Granger CB, McMurray JJ, Yusuf S, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772-6.
91. Ljungman S, Kjekshus J, Swedberg K. Renal function in severe congestive heart failure during treatment with enalapril (the Cooperative North Scandinavian Enalapril Survival Study \[CONSENSUS\] Trial). The American journal of cardiology 1992;70:479-87.
92. Rossignol P, Cleland JG, Bhandari S, et al. Determinants and consequences of renal function variations with aldosterone blocker therapy in heart failure patients after myocardial infarction: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study. Circulation 2012;125:271-9.
93. Vardeny O, Wu DH, Desai A, et al. Influence of baseline and worsening renal function on efficacy of spironolactone in patients With severe heart failure: insights from RALES (Randomized Aldactone Evaluation Study). Journal of the American College of Cardiology 2012;60:2082-9.
94. Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777-81.
95. Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP. Potential effects of aggressive decongestion
during the treatment of decompensated heart failure on renal function and survival. Circulation 7 2010;122:265-72.
96. Kataoka H. Phenomenon of paradoxical improvement in renal function defined by a decreased concentration of serum creatinine despite heart failure worsening. International journal of cardiology 2014;176:1392-5.
97. Flesch M, Erdmann E. The problem of polypharmacy in heart failure. Curr Cardiol Rep 2006;8:217-25.
98. Oni-Orisan A, Lanfear DE. Pharmacogenomics in heart failure: where are we now and how can we reach clinical application? Cardiol Rev 2014;22:193-8.
99. Gaggin HK, Motiwala S, Bhardwaj A, Parks KA, Januzzi JL, Jr. Soluble concentrations of the interleukin receptor family member ST2 and beta-blocker therapy in chronic heart failure. Circulation Heart failure 2013;6:1206-13.
100. Gullestad L, Ueland T, Kjekshus J, et al. Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). European heart journal 2012;33:2290-6.
101. FiuzatM,SchultePJ,FelkerM,etal.Relationshipbetweengalectin-3levelsandmineralocorticoidreceptor antagonist use in heart failure: analysis from HF-ACTION. Journal of cardiac failure 2014;20:38-44.
102. Gandhi PU, Motiwala SR, Belcher AM, et al. Galectin-3 and mineralocorticoid receptor antagonist use in patients with chronic heart failure due to left ventricular systolic dysfunction. American heart journal 2015;169:404-11 e3.
103. Braunwald E. Biomarkers in heart failure. Preface. Heart Fail Clin 2009;5:xiii-xiv.
General Discussion
169